Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Texas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Texas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Texas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Haris Zahoor (NPI 1700017217)

Field	Value
Entity Type	Individual
Organization	Haris Zahoor
Address	1919 Old Spanish Trl Fl 6
City	Houston
State	TX
ZIP	77054
Taxonomy	Medical Oncology Physician
NPI Enumerated	July 31, 2009

Payer Source	Total Paid
Medicare	$1.6M
Medicaid	$0

Key Findings

This provider’s Medicare activity is material at $1.6M in lifetime Medicare revenue while there is no Medicaid billing on file, making the practice effectively single-payer (Medicare) in the available claims data. The absence of any Medicaid codes suggests limited state-program exposure and a payer mix concentrated on fee-for-service Medicare reimbursement.

Revenue concentration is high: the top 3 Medicare codes account for 56.6% of this provider’s total Medicare revenue, dominated by J9299 ($339.8K, 21.4%), J9271 ($335.4K, 21.1%), and J9144 ($225.7K, 14.2%). This concentration shows that a majority of Medicare dollars are driven by a few high-cost oncology injectables rather than broad E/M or ancillary services.

The code mix is characteristic of a medical oncology infusion practice: frequent billing for checkpoint inhibitors and monoclonal antibodies (J9299, J9271, J9144) alongside supportive and growth-factor agents such as J0897 (denosumab, $203K) and J2506 (pegfilgrastim, $42.2K). Combined with chemotherapy administration codes like 96413 and infusion-related codes 96365/96367, the pattern indicates in-office infusion services and oncology medical management as core operations.

Against national peers this provider is a modest participant for the top biologics: J9299 ranks #266 of 505 providers (47th percentile), J9271 ranks #1430 of 1841 (21st percentile), and J9144 ranks #433 of 615 (28th percentile), each labeled as typical, unremarkable volume. These rankings indicate the practice is not a dominant national center for these drugs but does have consistent utilization.

Non-drug services show relatively high throughput in certain areas: 99215 is notably above typical national volume (96th percentile) with $39.3K in revenue, and phlebotomy and lab panel volumes are also high (36415 at the 97th percentile, 80053 at the 94th percentile, and 85025 at the 95th percentile). This suggests the practice manages complex outpatient visits and substantial ancillary testing, supporting ongoing oncology treatment and monitoring.

Imaging and diagnostic activity supports an oncology workflow: PET/CT (78815) generated $74.2K (4.7% of Medicare revenue) and other imaging codes including 78816, 74177, and 71260 appear on the top list. The presence of A9552 (FDG dose) and combined PET/CT billing indicates frequent use of advanced imaging to stage or follow malignancies as part of the treatment pathway.

Tenure data show the NPI was enumerated on 2009-07-31 (~17 years ago), which is consistent with an established practice and long-standing Medicare billing relationships. This length of enumeration supports stability in clinical operations and payer interactions.

Operational and payer-risk implication: because over half of Medicare revenue is tied to three injectable oncology drugs (56.6% concentrated in J9299, J9271, J9144), changes in drug reimbursement, utilization guidelines, or access to these agents could materially affect revenue. At the same time, having no Medicaid billing reduces exposure to lower Medicaid rates but increases dependence on Medicare dynamics and commercial coverage for overall volume sustainability.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

67 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9299	Injection, nivolumab, 1 mg	14,160	$20	$339.8K
J9271	Injection, pembrolizumab, 1 mg	7,800	$40	$335.4K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	5,940	$40	$225.7K
J0897	Injection, denosumab, 1 mg	11,280	$20	$203K
J1449	Injection, eflapegrastim-xnst, 0.1 mg	3,300	$30	$82.5K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	70	$1,090	$74.2K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	460	$90	$42.3K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	480	$90	$42.2K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	300	$130	$39.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	330	$90	$30.9K

Showing 1–10 of 67

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 67 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Texas Distribution

Haris Zahoor — 3 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Texas

Full comparison — all codes billed, vs. state median

67 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	24	230	10,700	$40	$516.5K
J9299	10	30	8,800	$20	$340.2K
J9144	9	30	5,850	$40	$244.6K
J1449	5	10	3,170	$30	$121.3K
J0897	8	650	2,580	$20	$79.2K
J3490	23	350	60	$480	$54.4K
78815	28	600	40	$460	$47.5K
88185	6	80	560	$20	$45.7K
J1439	23	70	32,250	$1	$33K
J2506	7	70	310	$80	$29.5K

Showing 1–10 of 67

Related Providers

Other providers that share a Tax Identification Number (TIN) with Haris Zahoor, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Bryan Medical Center	NE	General Acute Care Hospital	$0	$56.9M
Alegent Creighton Clinic	NE	Family Medicine Physician	$0	$43.2M
Usc Care Medical Group, Inc	CA	General Practice Physician	$0	$39.1M
Khaled Tawansy	CA	Ophthalmology Physician	$2.8M	$2.4M
Cameron Pole	CA	Ophthalmology Physician	$4.5M	$0
The Physician Network	NE	Family Medicine Physician	$0	$3.1M
Eric Avery	NE	Hematology & Oncology Physician	$3.1M	$0
Kailash Mosalpuria	NE	Hematology & Oncology Physician	$2.9M	$0
Chi Health Clinic Specialty, LLC	NE	Hospitalist Physician	$0	$2.6M
Madhu Midathada	NE	Hematology & Oncology Physician	$2.3M	$0

Nearby Providers

Other providers in the same ZIP code as Haris Zahoor, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Tcg Interests, LLC	TX	Durable Medical Equipment & Medical Supplies	$0	$52.4M
Texas Quality One Medical Services Inc.	TX	Personal Care Attendant	$0	$31.7M
Siblings Healthcare Solutions LLC	TX	Home Health Agency	$0	$19.7M
National Seating & Mobility, Inc.	TX	Durable Medical Equipment & Medical Supplies	$0	$17.7M
Option Care Enterprises, Inc.	TX	Home Infusion Therapy Pharmacy	$0	$13.8M
Optimal In Home Care Inc.	TX	Personal Care Attendant	$0	$13.6M
United Seating And Mobility LLC	TX	Durable Medical Equipment & Medical Supplies	$0	$11.6M
Privia Medical Group Gulf Coast, PLLC	TX	Obstetrics & Gynecology Physician	$0	$11.3M
Access Dx Laboratory LLC	TX	Clinical Medical Laboratory	$458.3K	$4.3M
Ignacio Valdes	TX	Psychiatry Physician	$404.4K	$2.1M

Haris Zahoor — Billing Profile & Reimbursement Data

Sign up for Haris Zahoor — Billing Profile & Reimbursement Data policy alerts

Haris Zahoor — Billing Profile & Reimbursement Data

Sign up for Haris Zahoor — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References